A molecularly integrated grade for meningioma
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology..
BACKGROUND: Meningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management.
METHODS: We evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms.
RESULTS: We developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score.
CONCLUSION: We propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Neuro-oncology - 24(2022), 5 vom: 04. Mai, Seite 796-808 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Driver, Joseph [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Copy-number alterations |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 19.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/neuonc/noab213 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330508512 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330508512 | ||
| 003 | DE-627 | ||
| 005 | 20231225211432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/noab213 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330508512 | ||
| 035 | |a (NLM)34508644 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Driver, Joseph |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A molecularly integrated grade for meningioma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. | ||
| 520 | |a BACKGROUND: Meningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management | ||
| 520 | |a METHODS: We evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms | ||
| 520 | |a RESULTS: We developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score | ||
| 520 | |a CONCLUSION: We propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a copy-number alterations | |
| 650 | 4 | |a meningioma | |
| 700 | 1 | |a Hoffman, Samantha E |e verfasserin |4 aut | |
| 700 | 1 | |a Tavakol, Sherwin |e verfasserin |4 aut | |
| 700 | 1 | |a Woodward, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Maury, Eduardo A |e verfasserin |4 aut | |
| 700 | 1 | |a Bhave, Varun |e verfasserin |4 aut | |
| 700 | 1 | |a Greenwald, Noah F |e verfasserin |4 aut | |
| 700 | 1 | |a Nassiri, Farshad |e verfasserin |4 aut | |
| 700 | 1 | |a Aldape, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Zadeh, Gelareh |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhury, Abrar |e verfasserin |4 aut | |
| 700 | 1 | |a Vasudevan, Harish N |e verfasserin |4 aut | |
| 700 | 1 | |a Magill, Stephen T |e verfasserin |4 aut | |
| 700 | 1 | |a Raleigh, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Abedalthagafi, Malak |e verfasserin |4 aut | |
| 700 | 1 | |a Aizer, Ayal A |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Brian M |e verfasserin |4 aut | |
| 700 | 1 | |a Ligon, Keith L |e verfasserin |4 aut | |
| 700 | 1 | |a Reardon, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Patrick Y |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Mefty, Ossama |e verfasserin |4 aut | |
| 700 | 1 | |a Ligon, Azra H |e verfasserin |4 aut | |
| 700 | 1 | |a Dubuc, Adrian M |e verfasserin |4 aut | |
| 700 | 1 | |a Beroukhim, Rameen |e verfasserin |4 aut | |
| 700 | 1 | |a Claus, Elizabeth B |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Ian F |e verfasserin |4 aut | |
| 700 | 1 | |a Santagata, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Wenya Linda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-oncology |d 1999 |g 24(2022), 5 vom: 04. Mai, Seite 796-808 |w (DE-627)NLM111754321 |x 1523-5866 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:5 |g day:04 |g month:05 |g pages:796-808 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/neuonc/noab213 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 5 |b 04 |c 05 |h 796-808 | ||